BTK and Miyoshi myopathy: BTK inhibition does not appear to be as cytotoxic to tumor cells as other treatments such as proteasome inhibitors or immunomodulators; however, the effect of targeting the MM stem cells and BM microenvironment may prove it to be an even more valuable and effective treatment in the long term and in relapsed/refractory (R/R) patients.